Minimum intervention dentistry in oral medicine

Australian Dental Journal

Volumn 58, Issue SUPPL.1, 2013, Pages 85-94

  Farah, C S ^a   Bhatia, N ^a   John, K ^a,b   Lee, B W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

early detection; Minimum intervention dentistry; oral cancer; oral medicine

Indexed keywords

ARTICLE; CONSERVATIVE TREATMENT; HEAD AND NECK TUMOR; HEALTH; HUMAN; METHODOLOGY; MOUTH TUMOR; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; STOMATOLOGY;

HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MOUTH NEOPLASMS; MULTIMODAL IMAGING; ORAL HEALTH; ORAL MEDICINE; ORGAN SPARING TREATMENTS; POSITRON-EMISSION TOMOGRAPHY; RISK ASSESSMENT;

EID: 84878535150     PISSN: 00450421     EISSN: 18347819     Source Type: Journal    
DOI: 10.1111/adj.12054     Document Type: Article

References (59)

1. Lajer CB, Von Buchwald C,. The role of human papillomavirus in head and neck cancer. APMIS 2010; 118: 510-519.
2. Lee JJ, Hong WK, Hittelman WN, et al,. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6: 1702-1710. (Pubitemid 30305062)
3. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E,. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008; 37: 127-133. (Pubitemid 351178405)
4. Feller L, Lemmer J,. Oral leukoplakia as it relates to HPV infection: a review. Int J Dent 2012; 2012: 540561.
5. Lodi G, Porter S,. Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med 2008; 37: 63-69.
6. Holmstrup P, Vedtofte P, Reibel J, Stoltze K,. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006; 42: 461-474.
7. Cardesa A, Nadal A,. Carcinoma of the head and neck in the HPV era. Acta Dermatovenerol Alp Panonica Adriat 2011; 20: 161-173.
8. Conway MJ, Meyers C,. Replication and assembly of human papillomaviruses. J Dent Res 2009; 88: 307-317.
9. Zheng ZM, Wang X,. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809: 668-677.
10. Li B, Hu Y, Ye F, Li Y, Lv W, Xie X,. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer 2010; 20: 597-604.
11. Joseph AW, D'Souza G,. Epidemiology of human papillomavirus-related head and neck cancer. Otolaryngol Clin North Am 2012; 45: 739-764.
12. Friedman RC, Farh KK, Burge CB, Bartel DP,. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
13. Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ,. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34 (Database issue): D140-144.
14. Miska EA,. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563-568. (Pubitemid 41262414)
15. Volinia S, Galasso M, Costinean S, et al,. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20: 589-599.
16. Babu JM, Prathibha R, Jijith VS, Hariharan R, Pillai MR,. A miR-centric view of head and neck cancers. Biochim Biophys Acta 2011; 1816: 67-72.
17. Calin GA, Sevignani C, Dumitru CD, et al,. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101: 2999-3004. (Pubitemid 38327724)
18. Calin GA, Dumitru CD, Shimizu M, et al,. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99: 15524-15529. (Pubitemid 35403967)
19. He L, Thomson JM, Hemann MT, et al,. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833. (Pubitemid 40839734)
20. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI,. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14: 2588-2592.
21. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW,. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012; 34: 219-224.
22. Patel RS, Jakymiw A, Yao B, et al,. High resolution of microRNA signatures in human whole saliva. Arch Oral Biol 2011; 56: 1506-1513.
23. Schulz BL, Cooper-White J, Punyadeera CK,. Saliva proteome research: current status and future outlook. Crit Rev Biotechnol. 2012 May 21 [Epub ahead of print].
24. Gomez I, Seoane J, Varela-Centelles P, Diz P, Takkouche B,. Is diagnostic delay related to advanced-stage oral cancer? A meta-analysis. Eur J Oral Sci 2009; 117: 541-546.
25. Pitchers M, Martin C,. Delay in referral of oropharyngeal squamous cell carcinoma to secondary care correlates with a more advanced stage at presentation, and is associated with poorer survival. Br J Cancer 2006; 94: 955-958.
26. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC,. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg 2003; 61: 751-758. (Pubitemid 36754024)
27. Sciubba JJ,. Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol 2001; 2: 239-251. (Pubitemid 32738666)
28. Farah CS, McCullough MJ,. Oral cancer awareness for the general practitioner: new approaches to patient care. Aust Dent J 2008; 53: 2-10.
29. Downer MC, Evans AW, Hughes Hallet CM, Jullien JA, Speight PM, Zakrzewska JM,. Evaluation of screening for oral cancer and precancer in a company headquarters. Community Dent Oral Epidemiol 1995; 23: 84-88.
30. Lim K, Moles DR, Downer MC, Speight PM,. Opportunistic screening for oral cancer and precancer in general dental practice: results of a demonstration study. Br Dent J 2003; 194: 497-502. (Pubitemid 38844030)
31. Brocklehurst P, Kujan O, Glenny AM, et al,. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev 2010;(11): CD004150.
32. Sankaranarayanan R, Ramadas K, Thomas G, et al,. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005; 365: 1927-1933. (Pubitemid 40797502)
33. Identafi. StarDental. URL: 'http://www.identafi.net/'. Accessed 26 October 2012.
34. Microlux/DL product information. AdDent, Inc. URL: 'http://www.addent. com/prod-microlux2.html'. Accessed 26 October 2012.
35. VELscope Vx,. LED Dental Inc. URL: 'http://www.velscope.com/default. aspx'. Accessed 26 October 2012.
36. ViziLite Plus Product Information. Zila Pharmaceuticals Inc. URL: 'http://www.zila.com/40/VIZILITE%26REG%3B%20PLUS/'. Accessed 26 October 2012.
37. McIntosh L, McCullough MJ, Farah CS,. The assessment of diffused light illumination and acetic acid rinse (Microlux/DL) in the visualisation of oral mucosal lesions. Oral Oncol 2009; 45: e227-231.
38. De Veld DC, Witjes MJ, Sterenborg HJ, Roodenburg JL,. The status of in vivo autofluorescence spectroscopy and imaging for oral oncology. Oral Oncol 2005; 41: 117-131. (Pubitemid 40202877)
39. Lane PM, Gilhuly T, Whitehead P, et al,. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt 2006; 11: 024006.
40. Poh CF, Zhang L, Anderson DW, et al,. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 2006; 12: 6716-6722. (Pubitemid 44876840)
41. Mehrotra R, Singh M, Thomas S, et al,. A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and cancerous oral lesions. J Am Dent Assoc 2010; 141: 151-156.
42. Awan KH, Morgan PR, Warnakulasuriya S,. Evaluation of an autofluorescence based imaging system (VELscope) in the detection of oral potentially malignant disorders and benign keratoses. Oral Oncol 2011; 47: 274-277.
43. Scheer M, Neugebauer J, Derman A, Fuss J, Drebber U, Zoeller JE,. Autofluorescence imaging of potentially malignant mucosa lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111: 568-577.
44. Farah CS, McIntosh L, Georgiou A, McCullough MJ,. Efficacy of tissue autofluorescence imaging (VELScope) in the visualization of oral mucosal lesions. Head Neck 2012; 34: 856-862.
45. Piazza C, Cocco D, Del Bon F, et al,. Narrow band imaging and high definition television in evaluation of oral and oropharyngeal squamous cell cancer: a prospective study. Oral Oncol 2010; 46: 307-310.
46. Muto M, Minashi K, Yano T, et al,. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol 2010; 28: 1566-1572.
47. Katada C, Tanabe S, Koizumi W, et al,. Narrow band imaging for detecting superficial squamous cell carcinoma of the head and neck in patients with esophageal squamous cell carcinoma. Endoscopy 2010; 42: 185-190.
48. Tan NC, Herd MK, Brennan PA, Puxeddu R,. The role of narrow band imaging in early detection of head and neck cancer. Br J Oral Maxillofac Surg 2012; 50: 132-136.
49. Watanabe A, Taniguchi M, Tsujie H, Hosokawa M, Fujita M, Sasaki S,. The value of narrow band imaging endoscope for early head and neck cancers. Otolaryngol Head Neck Surg 2008; 138: 446-451. (Pubitemid 351400271)
50. Nguyen P, Bashirzadeh F, Hodge R, et al,. High specificity of combined narrow band imaging and autofluorescence mucosal assessment of patients with head and neck cancer. Head Neck 2013; 35: 619-625.
51. Beyer T, Townsend DW, Brun T, et al,. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379. (Pubitemid 30643379)
52. Loeffelbein DJ, Souvatzoglou M, Wankerl V, et al,. PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg 2012; 70: 473-483.
53. Weber WA,. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-3292. (Pubitemid 46622068)
54. Platzek I, Beuthien-Baumann B, Schneider M, et al,. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging 2012 Sep 28 [Epub ahead of print].
55. Sigg MB, Steinert H, Gratz K, Hugenin P, Stoeckli S, Eyrich GK,. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg 2003; 61: 1022-1029. (Pubitemid 37064695)
56. Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G,. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR Am J Neuroradiol 2010; 31: 598-604.
57. Higgins KA, Hoang JK, Roach MC, et al,. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 2012; 82: 548-553.
58. Kubicek GJ, Champ C, Fogh S, et al,. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2010; 2: 19.
59. Heuveling DA, De Bree R, Van Dongen GA,. The potential role of non-FDG-PET in the management of head and neck cancer. Oral Oncol 2011; 47: 2-7.